Could be that Genomeweb story on PBSC you posted (g)... but more likely this -
LONDON, Jan 23 (Reuters) - Oxford Glycosciences Plc shares dropped to an 11-month low on Tuesday, amid talk that at least two leading brokerages were selling stock on behalf of U.S. funds, dealers said.
Shares in the company -- a specialist in proteomics, or the role of proteins in disease -- were down 177-1/2 pence or 13 percent at 1,192-1/2p by 1510 GMT, having dropped as low as 1,150p, their lowest since last February.
The decline made Oxford Glyco the worst performer in the FTSE 250 index of midrange stocks.
"There have been a couple of U.S. sell orders in the market," said one dealer, adding that one brokerage had been looking to place some 100,000 shares.
Oxford Glyco shares plummeted last November when the company unveiled plans for a share issue to fund new research and possible future acquisitions.
The issue eventually raised a greater-than-expected 170 million pounds, after being priced at 1,275p per share -- a deep discount to their 2,290p level before the offer was annouced.
(my own view, FWIW, is that it's an excellent company that's somewhat disfunctional when it comes to dealing with US investors...) |
